Test lead compounds on our patented sporadic Alzheimer's disease model.

our approach

​Strong of its results after years of research by world renowned Dr. Gilbert Bernier, STEMAXON TM  provides a new platform (patent pending) for the pharmaceutical industry to test their lead compounds against AD. 

This unique platform greatly increase the efficiency to validate existing molecules for drug development and treatment.  Currently, pharmaceutical companies can require up to 5 years validating a single molecule compound, using this platform, the same results can be completed in less than 6 months.  

- Drug Testing for current lead Alzheimer’ disease (AD) compounds in human cortical neurons.

- Drug Development, Screening and Test for new compounds.   

- Gene therapy (AAV vector) and drug-therapy research specifically targeting sporadic AD gene   or protein function for the treatment of AD.